

# 1 **Stretch-activated ion channel TMEM63B associates with developmental and** 2 **epileptic encephalopathies and progressive neurodegeneration**

3  
4 Annalisa Vetro<sup>1\*</sup>, Simona Balestrini<sup>1,2,3\*</sup>, Cristiana Pelorosso<sup>1\*</sup>, Alessio Masi<sup>4</sup>, Sophie Hambleton<sup>5,6</sup>,  
5 Emanuela Argilli<sup>7</sup>, Valerio Conti<sup>1</sup>, Simone Giubbolini<sup>8</sup>, Rebekah Barrick<sup>9</sup>, Gaber Bergant<sup>10</sup>, Karin  
6 Writzl<sup>10</sup>, Emilia K. Bijlsma<sup>11</sup>, Theresa Brunet<sup>12,13</sup>, Pilar Cacheiro<sup>14</sup>, Davide Mei<sup>1</sup>, Anita Devlin<sup>5,6</sup>,  
7 Mariëtte J.V. Hoffer<sup>11</sup>, Keren Machol<sup>15</sup>, Guido Mannaioni<sup>4</sup>, Masamune Sakamoto<sup>16</sup>, Manoj P.  
8 Menezes<sup>17</sup>, Thomas Courtin<sup>18,19</sup>, Elliott Sherr<sup>7</sup>, Riccardo Parra<sup>8</sup>, Ruth Richardson<sup>20</sup>, Tony  
9 Roscioli<sup>21,22</sup>, Marcello Scala<sup>23</sup>, Celina von Stülpnagel<sup>13,24</sup>, Damian Smedley<sup>14</sup>, TMEM63B  
10 collaborators\*\*, The Genomics England Research Consortium<sup>8</sup>, Annalaura Torella<sup>25,26</sup>, Jun  
11 Tohyama<sup>27</sup>, Reiko Koichihara<sup>28</sup>, Keisuke Hamada<sup>29</sup>, Kazuhiro Ogata<sup>29</sup>, Takashi Suzuki<sup>30</sup>, Atsushi  
12 Sugie<sup>31</sup>, Jasper J. van der Smagt<sup>32</sup>, Koen van Gassen<sup>32</sup>, Stephanie Valence<sup>33</sup>, Emma Vittery<sup>20</sup>,  
13 Mitsuhiro Kato<sup>33</sup>, Naomichi Matsumoto<sup>16</sup>, Gian Michele Ratto<sup>8</sup>, and Renzo Guerrini<sup>1,2,#</sup>

14  
15 **\*These authors contributed equally to this work.**

## 16 17 **Author affiliations:**

- 18 1. Neuroscience Department, IRCCS Meyer Children's Hospital, Florence, Italy
- 19 2. University of Florence, Florence, Italy
- 20 3. Department of Clinical and Experimental Epilepsy, Partner of the ERN EpiCARE, UCL  
21 Queen Square Institute of Neurology, London, UK and Chalfont Centre for Epilepsy, Bucks,  
22 UK.
- 23 4. Department of Neuroscience, Psychology, Drug Research and Child Health (NeuroFarBa),  
24 Section of Pharmacology and Toxicology, University of Florence, Florence, Italy

**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

- 25 5. Newcastle University Translational and Clinical Research Institute, Newcastle upon Tyne,  
26 UK
- 27 6. Great North Children's Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, UK
- 28 7. Department of Neurology and Institute of Human Genetics and Weill Institute for  
29 Neurosciences, University of California, San Francisco, San Francisco, CA, USA
- 30 8. National Enterprise for NanoScience and NanoTechnology (NEST), Istituto Nanoscienze,  
31 Consiglio Nazionale delle Ricerche (CNR) and Scuola Normale Superiore Pisa, Pisa, Italy
- 32 9. Division of Metabolic Disorders, Children's Hospital of Orange County (CHOC), Orange,  
33 CA, USA
- 34 10. Clinical Institute of Genomic Medicine, University Medical Centre Ljubljana, Ljubljana,  
35 Slovenia
- 36 11. Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands
- 37 12. Institute of Human Genetics, School of Medicine, Technical University Munich, Munich,  
38 Germany
- 39 13. Department of Pediatric Neurology and Developmental Medicine, Dr. v. Hauner Children's  
40 Hospital, LMU - University of Munich, München, Germany
- 41 14. William Harvey Research Institute, Queen Mary University of London, London, UK
- 42 15. Department of Molecular and Human Genetics, Baylor college of Medicine, Houston, TX  
43 77030, USA
- 44 16. Department of Human Genetics, Yokohama City University Graduate School of Medicine,  
45 Yokohama, 236-0004 Japan
- 46 17. Department of Neurology, The Children's Hospital at Westmead and the Children's Hospital  
47 at Westmead Clinical School, University of Sydney, Westmead, Australia
- 48 18. Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, Paris,  
49 France

- 50 19. Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Département de Génétique,  
51 DMU BioGeM, Paris, France
- 52 20. Northern Genetics Service, Newcastle upon Tyne hospitals NHS Foundation Trust,  
53 Newcastle, UK
- 54 21. New South Wales Health Pathology Randwick Genomics, Prince of Wales Hospital, Sydney,  
55 NSW 2031, Australia
- 56 22. Neuroscience Research Australia, Sydney, NSW 2031, Australia
- 57 23. Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child  
58 Health, University of Genoa, Genoa, Italy
- 59 24. Institute for Transition, Rehabilitation and Palliation, Paracelsus Medical University,  
60 Salzburg, Austria
- 61 25. Department of Precision Medicine, University "Luigi Vanvitelli", Naples, Italy
- 62 26. Telethon Institute of Genetics and Medicine (TIGEM), Pozzuoli, Italy
- 63 27. Department of Child Neurology, Nishi-Niigata Chuo National Hospital, Niigata 950-2085,  
64 Japan
- 65 28. Department for Child Health and Human Development, Saitama Children's Medical Center,  
66 Saitama 330-8777, Japan.
- 67 29. Department of Biochemistry, Yokohama City University Graduate School of Medicine,  
68 Yokohama 236-0004, Japan
- 69 30. School of Life Science and Technology, Tokyo Institute of Technology, Yokohama,  
70 Kanagawa, Japan
- 71 31. Brain Research Institute, Niigata University, Niigata 951-8585, Japan
- 72 32. Department of Genetics, University Medical Center Utrecht, Utrecht, The Netherlands
- 73 33. Centre de référence Maladies Rares “Déficience intellectuelle de cause rare”; Département de  
74 Neuropédiatrie, Hôpital Armand Trousseau, APHP, Sorbonne Université, Paris, France
- 75 34. Department of Pediatrics, Showa University School of Medicine, Tokyo 142-8666, Japan

76

77

78 **#Correspondence to: Professor Renzo Guerrini**

79 Neuroscience Department

80 Meyer Children's University Hospital

81 Viale Pieraccini 24, 50139 Florence, Italy

82 tel: +39 0555662573

83 E-mail: [r.guerrini@meyer.it](mailto:r.guerrini@meyer.it)

84

85 **Keywords:** epilepsy; infantile spasms; abnormal myelination; white matter abnormality; genetic  
86 diseases; ion channels; leak cation currents

87

88 **Conflict-of-interest statement:** The authors have declared that no conflict of interest exists.

89

90 **Abstract**

91 By converting physical forces into electrical signals or triggering intracellular cascades, stretch-  
92 activated ion channels (SACs) allow the cell to respond to osmotic and mechanical stress. Knowledge  
93 of the pathophysiological mechanisms underlying associations of SACs with human disease is  
94 limited. Here we describe 16 unrelated patients, with severe early onset developmental and epileptic  
95 encephalopathy (DEE), intellectual disability, and severe motor and cortical visual impairment,  
96 associated with progressive neurodegenerative brain changes, carrying ten distinct *de novo* variants  
97 of *TMEM63B*, encoding for a highly conserved SAC. Variants were missense, including the recurrent  
98 V44M in 7/16 patients, or in-frame, and affected conserved residues located in transmembrane  
99 regions of the protein. In 12 patients, haematological abnormalities co-occurred, such as macrocytosis  
100 and haemolysis, requiring blood transfusions in some. We modelled V44M, R443H, and T481N in  
101 transfected Neuro2a cells and demonstrated leak inward cation currents across the mutated channel  
102 even in isotonic conditions, while the response to hypo-osmotic challenge was impaired, as were the  
103 Ca<sup>2+</sup> transients generated under hypo-osmotic stimulation. Ectopic expression of the V44M and  
104 G580C variants in *Drosophila* resulted in early death. *TMEM63B*-associated DEE represents a novel  
105 clinicopathological entity in which altered cation conductivity results in a severe neurological  
106 phenotype with progressive brain damage and early onset epilepsy, associated with haematological  
107 abnormalities in most patients.

108

## 109 **Introduction**

110 *TMEM63B*, with its two paralogues *TMEM63A* and *C*, belongs to a gene family initially identified as  
111 the closest homologues of the OSCA proteins, representing the largest family of stretch-activated ion  
112 channels conserved across eukaryotes (1, 2). In plants, members of the OSCA family sense osmotic  
113 stress-induced mechanical forces across the plasma membrane and activate a signalling pathway  
114 responsible for regulating water transpiration and root growth (1, 3). In mammals, members of the  
115 *TMEM63* family mediate cation currents in response to osmotic and mechanical stimuli affecting  
116 membrane tension (1, 4). This process is crucial for cell volume regulation and viability, as changes  
117 in osmolarity may cause water influx or efflux through the plasma membrane, resulting in cell  
118 swelling or shrinkage (5).

119 Other members of the *TMEM63* family have been associated with monogenic disorders, namely  
120 “transient infantile hypomyelinating leukodystrophy-19 (HLD19)” (MIM #618688), with  
121 developmental delay of variable severity, caused by heterozygous *TMEM63A* variants (6–8), and  
122 “autosomal recessive spastic paraplegia-87 (SPC-87)” (MIM #619966), caused by biallelic truncating  
123 variants of *TMEM63C* (9). The *TMEM63B* gene still lacks a clear association with human diseases,  
124 and it is not yet listed either in the OMIM's Morbid Map of the Human Genome or in the ClinGen  
125 Gene-Disease Validity database (<https://www.clinicalgenome.org/>). Multiple *Tmem63b* mRNA  
126 isoforms have been identified in mice, with post-transcriptional modifications contributing to mRNAs  
127 diversity (10). A brain-specific *Tmem63b* isoform, exhibiting alternative splicing of exon 4 and  
128 glutamine to arginine change (Q/R) at exon 20 has been shown to regulate Ca<sup>2+</sup> permeability and  
129 osmosensitivity of the channel (10). According to GTEx portal (<https://www.gtexportal.org/home/>),  
130 multiple *TMEM63B* mRNA isoforms also occur in humans, with different tissue specificity.

131

132 We identified ten distinct heterozygous *de novo* variants of *TMEM63B* in 16 unrelated patients with  
133 early onset developmental and epileptic encephalopathy (DEE), all associated with white matter

134 disease, corpus callosum abnormalities, and variable cortical, cerebellar, and haematological  
135 abnormalities.

136 After determining the most represented brain *TMEM63B* isoform in humans, we tested *in vitro* the  
137 effect of selected variants on the protein localisation and function by immunocytochemistry, whole-  
138 cell patch clamp, and calcium imaging in transfected Neuro2a cells. We also modelled *in vivo* in  
139 *Drosophila* the effects of the ectopic expression of two variants. Our findings indicate that  
140 heterozygous variants of *TMEM63B* result in a novel and clinically recognizable DEE syndrome  
141 whose pathophysiology relies in altered functional properties of the channel.

142

## 143 **Results**

144

### 145 **Clinical findings**

146 Clinical, EEG, and MRI findings of the 16 patients are summarized in Table 1 and Supplementary  
147 Table 1. They were all unrelated individuals who exhibited a markedly overlapping DEE phenotype  
148 with early onset drug-resistant epilepsy (16/16, 100%), severe developmental delay (16/16, 100%),  
149 early generalised hypotonia evolving to spastic quadriparesis (13/16, 81%), nystagmus and central  
150 visual impairment (11/16, 69%). Epilepsy onset ranged from birth to 3 years but occurred within the  
151 first year in 13/16 (81%) and in the first month of life in 5/16 (31%). A common pattern of the epilepsy  
152 phenotype was early onset of focal seizures (10/16, 67%), often manifested as apnoeic episodes in  
153 newborns, followed over months by epileptic spasms (5/16, 31%) or by different types of focal and  
154 generalised onset seizures (6/16, 38%). Infantile epileptic spasms, which were the initial  
155 manifestation of epilepsy in three additional patients (3/16, 19%), had therefore been present in 9/16  
156 patients (56%). In two remaining patients (2/16, 13%), onset was between age 2-3 years with focal  
157 seizures with impaired awareness. Epilepsy was severe at onset in all patients, with episodes of status

158 epilepticus in three (3/16, 19%). At last follow-up, five patients (5/16, 31%) had no longer severe  
159 epilepsy, including three who had experienced prolonged seizure freedom on medication (3/16, 19%).  
160 EEGs showed slow background activity with bilateral independent or multifocal epileptiform  
161 discharges in most patients.

162 All patients (16/16, 100%) had global developmental delay, with moderate to profound intellectual  
163 disability and severe motor impairment; only two had developed communicative language skills  
164 (2/16, 13%). Severe dysphagia was present in ten patients (10/16, 63%), requiring a percutaneous  
165 endoscopic gastrostomy (PEG) insertion in eight (8/16, 50%). In 12 patients (12/16, 75%) clinical  
166 history revealed haematological abnormalities resulting in abnormal haemoglobin levels, often with  
167 macrocytosis, and signs of haemolysis (hyperbilirubinemia, jaundice, hepatosplenomegaly), with a  
168 fluctuating course. In four of the 12 patients (4/12, 33%) with haematological abnormalities, three of  
169 whom carrying the recurrent V44M variant, anaemia was severe and required blood transfusions (Pts  
170 4, 6, 8, 12). In Pt 4, peripheral blood film showed abnormally shaped red cells (RBCs) with  
171 elliptocytes and increased stomatocytes. Bone marrow biopsy was performed in two patients (Pts 4  
172 and 8, 2/16, 13%) with signs of haemolysis in both, and evidence for haematopoiesis and  
173 myelodysplastic syndrome with aplastic anaemia in Pt 8 (Supplementary Figure 1). Growth  
174 parameters at birth were abnormal in terms of weight (<3<sup>rd</sup> percentile in 1/16, 6% and >99<sup>th</sup> in 1/16,  
175 6%) and length (<3<sup>rd</sup> pc in 3/16, 19%). Patients with normal birth growth parameters showed  
176 subsequent signs of growth failure (<3<sup>rd</sup> pc, 6/16, 38%). Two patients (2/16, 13%) had died  
177 prematurely due to pneumonia (Pts 4 and 6; Table 1). Microcephaly was present in three patients  
178 (3/16, 19%), in one of them since birth along with severe haemolytic anaemia (Pt 12).

179 Prompted by the evidence for progressive hearing loss in *Tmem63b* deleted mice (4), we investigated  
180 whether any clinical sign of hearing impairment had occurred, reviewed the results of formal hearing  
181 testing in 10/16 (63%) patients, and found no relevant abnormalities.

182

## 183 **Magnetic resonance imaging findings**



184 All patients had at least one brain MRI scan at 1.5 or 3T between ages one week and 28 years, and  
185 11 patients were studied with two or more scans taken six months to 13 years apart (Table 1 and  
186 Figure 1). MRI revealed an association of multiregional or widespread white matter signal  
187 abnormalities, dysmorphic lateral ventricles, thinning of corpus callosum (16/16, 100%), cerebellar  
188 atrophy (8/16, 50%), and atrophy of the cerebral cortex (7/16, 44%).

189 All the 11 individuals for whom repeated MRIs were available for comparison (Pts 1, 2, 4, 5, 7, 8, 9,  
190 12, and 14-16), exhibited clear morphological or signal signs resulting from the combination of  
191 maturational and disease-related progressive changes. For example, when cerebellar atrophy was  
192 present, there had always been evidence of atrophy progression from initial to follow-up imaging (Pts  
193 1, 2, 4, 5, 7, 8, and 14). White matter signal abnormalities (always present) appeared in early scans  
194 as severely delayed myelination that was better appreciated using T2-weighted imaging and later  
195 evident as diffuse or more circumscribed areas of high signal intensity changes in FLAIR (see Pts 1,  
196 5, 7, and 8 in Figure 1). In the only individual who had received control MRI scans at different adult  
197 ages (Pt 14), cerebellar and white matter changes continued to worsen between age 6-10y. Overall,  
198 white matter abnormalities, ventricular shape, and thinning of the corpus callosum exhibited similar  
199 longitudinal changes. Signs of progression of cortical atrophy were minor, if any, and proportional to  
200 overall volume shrinking. MRI also showed progressive thickening of the trabecular (spongy) bone  
201 of the skull in five patients (5/16, 25%; Pts 4, 8, 12, and 14 in Figure 1; Pt 9, not shown) four of whom  
202 had anaemia (Pts 4, 8, 9, and 12), with a myelodysplastic disorder in three (Pts 4, 8, and 12) while  
203 one had experienced episodes of hyperbilirubinemia (Pt 14).

## 205 **Genetic findings**

206 In these 16 patients, we identified ten distinct *TMEM63B* variants (Table 1, Figure 2) including nine  
207 missense substitutions and one in-frame deletion. None of them was present in publicly available  
208 allele frequency databases such as GnomAD and TOPMed, or in our internal dataset, and all were  
209 predicted to be damaging by multiple prediction tools (Supplementary Table 2). Available gene

210 constraint scores from GnomAD indicate that *TMEM63B* is globally highly intolerant to both loss-  
211 of-function (LoF; pLI score = 1.00; observed/expected, o/e LoF = 0.07) and missense (*Z* score = 4.22;  
212 o/e missense = 0.475) variants. In addition, all variants identified in our patients were in regions of  
213 the protein predicted to be intolerant to missense variations according to region-level metrics (Figure  
214 2B, Supplementary Figure 2) and all involved amino acids highly conserved among the vertebrate  
215 orthologues of the protein (Figure 2C, Supplementary Table 2), as well as the paralogues *TMEM63A*  
216 and *TMEM63C* (Supplementary Figure 3).

217 We noticed a complementary linear distribution on the protein sequence of the *TMEM63B* variants  
218 in our cohort versus the gene variants in the reference population from GnomAD. The latter were  
219 enriched in exons 3-14 and 22-24 and substantially depleted in exons 15-21, where our variants  
220 clustered (Figure 2B, Supplementary Figure 2). This observation, supported by the local constraint  
221 metrics provided by multiple tools, suggests an increased selective pressure in the region of the gene  
222 corresponding to the seven transmembrane domain region RSN1\_7TM (PF02714). This domain is  
223 conserved among osmosensitive calcium-permeable cation channels (11).

224 The V44M variant was recurrent in seven unrelated patients (Pts 1, 4-9) and two different changes  
225 affected the same residues in two patients (G580S in Pt 13 and G580C in Pt 14). Eight of the affected  
226 residues are fully conserved from human to zebrafish (V44, R443, D459, V463, T481, G580, R660,  
227 and F697), and one is fully conserved up to chicken (I475). In addition, six out of nine affected  
228 residues are fully conserved among all the three paralogues' sequences (V44, D459, V463, G580,  
229 R660, and F697), and three (R443, T481 and I475) among two of the three paralogues, maintaining  
230 strongly similar properties in the third (Supplementary Figure 3).

231 The *TMEM63B* variant occurred *de novo* in the 15 patients for whom parental DNA was tested.  
232 Patient 10 was born through gamete-donation and we could not analyse parental DNA.

233 Based on both *in silico* analyses using sequence data and the functional studies described below, we  
234 interpreted all variants as detrimental for the protein function.

235

## 236 **Structural considerations**

237 Since crystallographic data are not yet available for TMEM63B, we can only access information  
238 about the protein topology based on its partial homology with the plants' OSCAs, for a subset of  
239 whom crystallographic data are available (2, 12, 13). As the percentage of identity in protein sequence  
240 between mammals TMEM63A-C proteins and OSCAs is around 20% (1), mapping our variants on  
241 these structures would be inaccurate. Aware of the limitations of prediction tools in regions of low  
242 homology, we mapped our variants on the structure exhibiting more homogenous resolution across  
243 the protein, including both the transmembrane helices and the intracellular domains (Figure 3,  
244 Supplementary Figure 4). In our model, 81% of residues had >90% confidence, including all those  
245 affected by variants in our cohort, all affecting a predicted transmembrane (TM) helix (Figure 2A and  
246 3A, B). Five variants fell in TM4 (R433H, D459E, and V463I) or TM5 (I475del and T481N) (Figure  
247 3A, B, blue helices), whose tilting and rearrangement upon osmotic stimulus plays a role in channel  
248 opening in *Oryza sativa* OSCA1.2 protein (13). The remaining variants mapped in TM1 (V44M),  
249 TM7 (G580S and G580C), TM8 (R660T), and TM9 (F697L). All but the recurrent V44M variant are  
250 in the Pfam-classified domain RSN1\_7TM (11) and six of them affect the predicted pore-forming  
251 TM4-TM8 helices (2).

252 The V44M (Pts 1, and 4-9) lies in a region with limited sequence homology between OSCAs and  
253 TMEM63A-C, and for which available OSCAs structures have low resolution (2, 12). The Valine to  
254 Methionine substitution involves two amino acids with similar properties (Grantham distance 21;  
255 scale 0-215) and mass. The TM1 helix is located on the external surface of the channel and is not  
256 directly involved in the predicted pore, but seems to be rather involved, together with TM7, in the  
257 sensitivity to membrane stretching (2, 12) (Figure 2).

258 In a FoldX-based model, Met44 is predicted to make van der Waals contacts with Gln477, Phe478,  
259 and Thr481, all mapping on the TM4 helix (Supplementary Figure 5). Since the free energy change  
260 associated with V44M is negative (-1.46, calculated by FoldX), we hypothesize that this substitution  
261 may stabilize the protein structure.

262 We estimated evolutionary conservation and role of the mutated residues by ConSurf, which  
263 confirmed that all changes affected highly conserved residues with predicted functional and/or  
264 structural role (Supplementary Figure 6; Supplementary Table 3).

265 We also evaluated the structural impact of the nine distinct missense variants in our cohort using the  
266 Missense3D tool (14) and found that 8/9 may affect the protein structure, although limitedly, via  
267 changes in cavities volume (7/8), residues accessibility (3/8), and breakage of non-covalent bonds  
268 (2/8) (Supplementary Table 3). The D459E substitution (Pt 10) disrupts a salt bridge formed between  
269 OD2 atom of Asp459 and NZ atom of Lys460 (distances: 4.168 Å between OD2 atom of Asp450 and  
270 NZ atom of Lys460, 5.503Å between OE2 atom of Glu450 and NZ atom of Lys460) (Figure 3C).  
271 The G580S substitution (Pt 13) replaces a buried Glycine, with a residue solvent accessibility (RSA)  
272 of 5.9%, with a buried Serine with an RSA of 3.8%. In addition, OG atom of Ser580 might form a  
273 salt bridge with NE1 atom of Trp485 (W485), possibly stabilizing the structure of the pore (Figure  
274 3D). Substitution of the G580 amino acid with a Cysteine (G580C, Pt 14) introduces a bulkier residue  
275 at position 580 and changes its RSA from 5.9% to 3.7%. Although the free SH residue of C580 can  
276 make disulphide bonds with other amino acids with free SH residues, the distance between C580 and  
277 C486, which is the closer amino acid with a free SH residue (10.519Å; Figure 3E) does not allow the  
278 making of disulphide bonds. The R660T variant (Pt 15) replaces a buried charged Arginine (RSA  
279 5.6%) with an uncharged Threonine. This substitution also disrupts a salt bridge between NH<sub>2</sub> group  
280 of Arg660 and OD1 atom of Asp137 (distance: 4.787 Å) (Figure 3F). For V44M, R433H (Pt 2),  
281 V463I (Pt 11), and F697L (Pt 16), Missense3D suggests only mild alterations of the cavity volume  
282 (<70Å<sup>3</sup>), without significant structural changes, which might still influence the overall stability of the  
283 protein (Supplementary Table 3). It has indeed been demonstrated that cavities in membrane proteins  
284 play a pivotal role in balancing stability and flexibility, impacting protein function (15). For the  
285 T481N (Pt 3), which according to ConSurf affects a predicted structural residue, Missense3D did not  
286 indicate clear structural damage but could calculate cavity volume in the mutant structure. As for the

287 in-frame deletion variant I475del (Pt 12), Phyre2 modelling did not predict gross alterations of the  
288 secondary structure.

289

## 290 **Post transcriptional editing in *TMEM63B* mRNA from human cerebral cortex** 291 **and selection of variants for *in vitro* functional studies**

292 We reverse-transcribed RNA from a human cerebral cortex sample into cDNA and amplified by PCR  
293 the region around exon 4 (Supplementary Figure 7A). We found that exon 4 was missing in 80% of  
294 *TMEM63B* RNA (Supplementary Figure 7B, C). We further characterised the Q/R editing at exon 20  
295 in long and short *TMEM63B* isoforms by PCR and Sanger sequencing and found that the editing  
296 occurred only in the short isoform (Supplementary Figure 7D, E). Both the exon 4 splicing and Q/R  
297 editing findings are in line with previous observations in mice (10), except for lower Q/R editing  
298 occurrence in the human (~40%) than in mouse cortex (~80%) (Supplementary Figure 7E). Based on  
299 this, we decided to study the effects of selected *TMEM63B* variants *in vitro* by modelling them in the  
300 short non-edited isoform, which is the most abundant in the human cortex.

301 For our functional studies we selected three variants based on recurrence in multiple patients with  
302 overlapping clinical features (V44M) and on their location in critical transmembrane helices TM4  
303 (R433H) and TM5 (T481N), whose rearrangement is implicated in channel opening (13).

304

## 305 **V44M, R433H and T481N do not affect *TMEM63B* localisation at the plasma** 306 **membrane**

307 The *TMEM63B* channel normally localises at the plasma membrane level (16, 17). To address the  
308 impact of V44M, R433H and T481N on *TMEM63B* localisation, we performed  
309 immunocytochemistry on Neuro2A cells transfected with GCaMP6f plasmids overexpressing either  
310 WT (wild-type) or mutant HA-tagged *TMEM63B*, and GCaMP6f empty vector as control.

311 We observed that, both in WT and mutant Neuro2A cells, TMEM63B was correctly localised at the  
312 membrane level (Figure 4). As expected, we did not observe any fluorescence emission in the red  
313 channel in GCaMP6f control cells. These findings suggest that all three variants we studied exert their  
314 effect by altering the channel function without impacting its localisation on the plasma membrane.

### 315 316 **V44M, R433H and T481N affect TMEM63B conductance**

317 In physiological conditions, TMEM63B operates as a non-selective cationic channel activated by  
318 mechanical and osmotic stimuli (1, 4). To address the impact of the selected V44M, R433H, and  
319 T481N variants on channel properties, we applied a set of electrophysiological protocols previously  
320 implemented to characterise WT TMEM63B *in vitro* (4) (Figure 5, Supplementary Figure 8). In  
321 transfected Neuro2A cells, we initially recorded whole-cell currents elicited by a -80 to +80 mV  
322 voltage ramp protocol in isotonic conditions (300 mOsm/L extracellular solution) and then imposed  
323 a hypo-osmotic stimulus by switching to a 170 mOsm/L solution.

324 In mutant TMEM63B cells, a -80 mV step imposed under isotonic conditions elicited a stable inward  
325 current that was absent in WT TMEM63B or GCAMP6f control cells (Figure 5A, B). Outward  
326 currents elicited at +80 mV were also significantly enhanced in cells expressing V44M, R433H, and  
327 T481N mutants compared to controls (Figure 5C). These three variants also caused a significant  
328 depolarization of the reversal potential, as shown by the current-voltage (I/V) relationship (Figure  
329 5A, D).

330 Under hypo-osmotic conditions, a -80 mV step elicited an inward current in cells expressing either  
331 the WT or mutant TMEM63B, while no current was generated in control cells (Supplementary Figure  
332 8). In most cases, cells underwent massive swelling and eventually burst, as previously reported (4).  
333 WT and mutant cells that sustained the hypo-osmotic shock and reached the plateau currents exhibited  
334 similar current amplitudes (Supplementary Figure 8A, B). The overall increase in currents observed  
335 at -80 mV, expressed as the delta ( $\Delta$ ) between currents measured under hypo-osmotic and isotonic

336 conditions, was larger in WT than in mutant TMEM63B expressing cells (Supplementary Figure 8C),  
337 as might be expected by a leak inward current under isotonic conditions in the mutant.  
338 Overall, these results show that V44M, R433H and T481N alter channel conductance, resulting in  
339 partial channel activation in physiological conditions, without altering the maximal channel  
340 conductance under hypo-osmotic stimulation.

341

### 342 ***TMEM63B* variants affect Calcium permeability**

343 Previous experiments conducted on Neuro2A cells led to identify TMEM63B as an osmosensitive  
344 nonselective cation channel activated by hypo-osmotic stress (4). In cochlear hair cells, where  
345 TMEM63B is particularly enriched, the Ca<sup>2+</sup> response is an essential element of the volume  
346 regulatory mechanism that protects cells viability from the osmotic challenge. Therefore, we  
347 wondered whether the clinically relevant *TMEM63B* variants might affect the hypo-osmotic induced  
348 Ca<sup>2+</sup> responses.

349 Hypo-osmotic challenges trigger cationic currents across the TMEM63B channel, with  
350 hyposmolarity-induced Ca<sup>2+</sup> influx (4). To determine whether the TMEM63B variants affect the  
351 hyposmolarity-induced Ca<sup>2+</sup> response, we co-expressed in Neuro2A cells the Ca<sup>2+</sup> sensor GCaMP6f  
352 and either WT TMEM63B or one of the three mutants V44M, R433H, and T481N. We performed  
353 calcium imaging under a confocal microscope in a recording chamber equipped with a perfusion  
354 system to deliver the test hypo-osmotic solutions to the cells. As previously reported (4), a hypo-  
355 osmotic stress provided by decreasing the osmolarity of the perfusion solution from 300 mOsm/L to  
356 170 mOsm/L triggered a Ca<sup>2+</sup> response (Figure 6A) in about 35% of WT TMEM63B cells, while  
357 only a small fraction of control cells transfected with GCaMP6f responded (Figure 6B). Neuro2A  
358 cells carrying V44M showed reduced responsivity with respect to the WT. We also tested the  
359 response to weaker osmotic stresses that are more likely to be representative of physiological changes,  
360 by shifting solution osmolarity from 300 mOsm/L down to 255 mOsm/L. The percentage of  
361 TMEM63B responsive cells decreased and all the three mutants showed a reduced responsivity score,



362 which was significant for R433H (Figure 6B). The time course of representative responses plotted in  
363 Figure 6A,C shows a heterogeneous behaviour of cells, ranging from transient  $\text{Ca}^{2+}$  pulses to  
364 sustained increments.

365 Given the role of  $\text{Ca}^{2+}$  in orchestrating the cell response to osmotic stress (4), we next analysed the  
366 amplitude and dynamics of the observed  $\text{Ca}^{2+}$  changes. All three variants showed smaller  $\text{Ca}^{2+}$   
367 transient compared to cells expressing WT *TMEM63B*. This is true when considering the maximal  
368 amplitude of the response (Figure 6D) and when considering the integral of the  $\text{Ca}^{2+}$  change computed  
369 for cells that returned to baseline within 150 seconds from the response onset (Figure 6E).

370

### 371 **V44M and G580C cause lethal toxicity in *Drosophila***

372 About two-thirds of the vital genes in the *Drosophila* genome are involved in eye development,  
373 including genes required for general cellular processes. For this reason, the fly eye provides an  
374 excellent experimental system to study the role of target genes in cellular function and development  
375 and in neurodevelopment/degeneration (18). To evaluate the potential impact of selected variants on  
376 the eye morphology, we generated transgenic flies expressing the human *TMEM63B* gene. We  
377 designed transgenes for the WT *TMEM63B*, the recurrent V44M, and the G580C variants, using the  
378 GMR-Gal4 ectopic expression system, which is mostly expressed in the retina (19). A schematic  
379 representation of the transgene construct is shown in Supplementary Figure 9A. The Gal4-UAS  
380 system (20) induces *TMEM63B* expression by the binding of the yeast transcription factor Gal4 to  
381 the UAS sequence. The expression level of the Gal4/UAS system increases in a temperature-  
382 dependent manner (19) and can therefore be modulated by changing the fly rearing temperatures. In  
383 WT *TMEM63B*-expressing flies, which were viable and reached the adult stage, we did not observe  
384 eye abnormalities (Supplementary Figure 9B, C). However, when expressing the V44M and G580C  
385 *TMEM63B* transgenes, we did not obtain any adult fly as both variants caused early lethality. We  
386 could not obtain any adult fly even after reducing the expression level of the two transgenes to the  
387 minimum by lowering the rearing temperature down to 18°C. In adult flies expressing WT *TMEM63B*



388 by *c739-Gal4*, we performed immunohistochemistry, and observed dotted signals on the cell  
389 membrane (Supplementary Figure 9D), thus demonstrating correct expression of the transgene in a  
390 neuronal cell type, Kenyon cells. We observed the same lethal phenotype by expressing the  
391 *TMEM63B* transgenes under either the *GMR-Gal4* or the *c739-Gal4* drivers, demonstrating that both  
392 variants caused lethal toxicity in *Drosophila*. Since the lack of either Kenyon cells or photoreceptors  
393 is not sufficient in itself to cause death in flies, we expect this phenotype to be caused by the  
394 expression of the V44M and G580C *TMEM63B* transgenes in other cell types indispensable during  
395 developmental stages.

396

## 397 **Discussion**

398 This series of 16 patients with pathogenic heterozygous *de novo* variants of *TMEM63B* defines the  
399 phenotypic features of an autosomal dominant early-onset DEE syndrome. All patients exhibited  
400 global developmental delay, moderate to profound intellectual disability, severe motor impairment,  
401 severe epilepsy with onset from birth to 3 years. Two patients had died prematurely and those who  
402 had reached adolescent or adult age remained completely dependent. Most had central visual  
403 impairment and swallowing dysfunction requiring PEG insertion. Epilepsy was a prominent feature  
404 and was quite severe at onset, featuring recurrent episodes of status in some patients, although a  
405 variable degree of seizure control was reported, with three patients achieving seizure-freedom on  
406 treatment. We noticed a common trajectory of the epilepsy phenotype, especially with the recurrent  
407 V44M variant, characterised by neonatal onset of apnoeic/focal seizures, evolving to epileptic spasms  
408 around the age of 4 to 6 months, and then continuing with focal, generalised seizures, or both. EEGs  
409 were consistent with an EE pattern at onset, including multifocal interictal epileptiform abnormalities  
410 and multiple seizure types in most. MRIs showed a consistent pattern of widespread or multiregional  
411 white matter abnormalities, with posterior periventricular predominance, dysmorphic lateral  
412 ventricles, thin corpus callosum, variably accompanied by global cerebellar atrophy (eight patients)  
413 and areas of cortical atrophy (six patients). Overall, initial MRI findings in most patients could be

414 misdiagnosed as consequence of perinatal hypoxic-ischemic cerebral injury (see for example Pts 1,  
415 3, 5, 7, 8, 12-15). However, longitudinal neuroimaging with relatively long-time interval (up to 13  
416 years) often revealed signs of progression, especially affecting the white matter and cerebellum. Over  
417 a clinical monitoring period up to ages 20 months to 30 years, two patients died at ages 0-5 years and  
418 11-15 years due to pneumonia. In the remaining 14 patients, clinical findings were consistent with a  
419 DEE akin to cerebral palsy in most, with limited signs of progression in ten (Pts 1, 2, 5, 7-9, 12, and  
420 14-16), and of a milder encephalopathy in four (Pts 3, 10, 11, and 13).

421 Overall, clinical and imaging findings are consistent with a progressive neurodegenerative clinical  
422 course and indicate, in most patients, prenatal central nervous system impairment leading to onset of  
423 symptoms early after birth or within the first year of life. Haematological abnormalities might have  
424 contributed to brain damage. In 12 patients, we found macrocytosis or signs of chronic haemolysis,  
425 often from birth, with a fluctuating course (Table 1, Supplementary Table 1). Although such  
426 abnormalities were mostly not clinically significant or only caused jaundice in the neonatal period, in  
427 four patients the anaemia was so severe to require periodic transfusions. In four of the patients with  
428 anaemia, MRI showed progressive thickening of the trabecular (spongy) bone of the skull (Pts 4, 8,  
429 and 12 in Figure 1 and Patient 9, not shown), a finding often associated with severe haematological  
430 disorders (21).

431 *TMEM63B* is evolutionarily conserved and highly intolerant to both loss-of-function and missense  
432 variants in the general population. The International Mouse Phenotyping Consortium (IMPC,  
433 <https://www.mousephenotype.org/>) lists *Tmem63b* among the essential genes in database since its  
434 homozygous knockout causes pre-weaning lethality in the C57BL/6N strain (22). Heterozygous  
435 *Tmem63b* mutant mice from the IMPC exhibits a neurodevelopmental phenotype and increased  
436 circulating bilirubin level, both consistent with observations in our patients. No further significant  
437 haematological or sensorial abnormalities were observed in this mouse model, but susceptibility to  
438 epilepsy (e.g., by Electroconvulsive Threshold Testing phenotypic assays) was not assessed. A more

439 vital C57BL/6N-FVB/N mixed breed surviving *Tmem63b*-knockout mice developed progressive  
440 hearing loss (4), a phenotype we did not observe in our patients.

441 Mendelian disease genes associated with autosomal dominant disorders are overrepresented among  
442 genes whose loss causes early-development lethality (DL) in mice (23). *TMEM63B* was prioritised  
443 among the potential candidates for human developmental disorders based on the overlap between  
444 genes that are DL in mouse and those carrying *de novo* variants in large-scale human rare disease  
445 sequencing data sets (23). Of five individuals with *de novo* *TMEM63B* variants included in the DDD  
446 (24) and 100KGP (25) studies, with minimal phenotypic information, we could retrieve detailed  
447 clinical data in three, which we added to this series (Pts 4, 6, and 7, Table 1).

448

449 All ten variants were distributed in a transmembrane domain conserved among osmosensitive  
450 calcium-permeable cation channels and affected residues under selective pressure in the general  
451 population, consistently with their predicted pathogenicity. None was a clear loss-of-  
452 function/haploinsufficient variant (e.g., causing frameshift or premature stop codon). Heterozygous  
453 deletions including *TMEM63B* are rarely reported in the Database of Genomic Variants, where at  
454 least two individuals carry truncating deletions removing most of the gene (<http://dgv.tcag.ca/>;  
455 supporting variants nssv1153700 nssv538990). Through our matchmaking initiative, we became  
456 aware of a patient with an unrelated phenotype and a homozygous truncating variant of *TMEM63B*  
457 (c.973C>T, R325\*), present in both healthy, heterozygous parents (unpublished data). These  
458 observations argue against haploinsufficiency being the obvious pathogenic mechanism in our cohort,  
459 as also supported by structural modelling and functional data. Structural modelling suggested mild  
460 changes in 8/10 of the variants, without a disruptive effect on the protein structure. All the ten variants  
461 affected transmembrane helices, including TM4-TM8, constituting the channel pore, or TM1 and  
462 TM7, involved in sensing membrane tension (2), and were predicted to cause minimal structural  
463 changes, such as disruption or creation of single salt bridges, and changes in cavities volumes. The  
464 predicted mutational consequences might therefore imply altered channel function, e.g. by stabilizing

465 the pore opening or affecting ion permeability and selectivity. In line with this hypothesis, and as  
466 expected for variants sparing protein folding, none of the three variants we tested *in vitro* impaired  
467 protein localisation in the plasma membrane.

468 V44M was recurrent in seven patients and the remaining variants clustered across a ~270 residues  
469 transmembrane region. Recurring mutations, as well as mutations with spatial clustering patterns,  
470 may exert their pathogenic effect through disease mechanisms other than LoF, such as gain-of-  
471 function (GoF) with enhanced activity or dominant-negative effects (26, 27).

472

473 In two independent *Drosophila* models, loss of *Tmem63* resulted in viable flies, not exhibiting gross  
474 defects in coordination, but lacking the ability to discriminate food texture or humidity (28, 29). In  
475 one of these models, the ectopic expression of the human *TMEM63B* gene in knockout flies rescued  
476 the defective phenotype in moisture attraction, demonstrating functional conservation of the two  
477 orthologues (29). We thus decided to model the V44M and G580C variants in *Drosophila*. However,  
478 both V44M and G580C *TMEM63B* transgenes caused lethal toxicity in our models. In contrast, the  
479 phenotype of the WT *TMEM63B*-expressing flies was indistinguishable from the control animals.  
480 These observations suggest that the variants we tested cause a toxic GoF of *TMEM63B*, rather than  
481 LoF.

482

483 Heterozygous variants of *TMEM63A* have been associated with developmental delay and  
484 hypomyelination (6–8). Disease-associated missense variants are enriched at amino acid sites that are  
485 conserved across paralogues (30) and differences in the clinical consequences of variants in  
486 paralogues may be due to different expression patterns and novel functions emerged with adaptive  
487 evolution (31). When aligning protein sequence of, and comparing variants positions in, *TMEM63B*  
488 and *TMEM63A* (Figure 1A, Supplementary Figure 2), we found that the Glycine 580 mutated to  
489 Serine in Pt 11 and to Cysteine in Pt 13 corresponds to the Glycine 567 recurrently mutated to Serine  
490 in *TMEM63A* in two unrelated patients with transient hypomyelination (6). G580S affects a buried

491 Glycine in TM7. In the Arabidopsis AtOSCA1.1 channel the corresponding Glycine 528 is located  
492 in a bending of the TM6 helix (2). Targeted mutagenesis of Glycine 528 to Alanine or Proline reduces  
493 the pressure necessary to elicit a current, suggesting that channel activation might involve  
494 straightening of M6 around Glycine 528 to relieve the blockage of the ion channel pore (2). According  
495 to *in silico* prediction and structural modelling, we might expect that both variants of Glycine 580  
496 stabilize the structure of the pore.

497

498 Multiple expression datasets indicate a complementary expression pattern between *TMEM63A* and  
499 *TMEM63B*, with the first being mainly expressed in oligodendrocytes and the second strongly  
500 expressed in neurons and to a lesser extent in astrocytes and oligodendrocyte precursor cells (OPC)  
501 (Supplementary Figure 10; <https://singlecell.broadinstitute.org>; <https://www.proteinatlas.org/>). The  
502 six patients reported to date with *TMEM63A* variants had follow-ups of variable duration and  
503 exhibited phenotypes that were either similar to our patients' (7, 8) or milder in those whose white  
504 matter changes improved with age (6), a phenomenon we did not observe.

505

506 For *in vitro* functional studies, we focused on the *TMEM63B* mRNA isoform most represented in the  
507 human cerebral cortex, the main generator of epileptogenic activity. Previous experiments in  
508 transfected Neuro2A cells suggested that the WT *TMEM63B* channel mediates non-selective cationic  
509 currents in response to hypo-osmotic stimulation (4). For the *in vitro* study of V44M, R433H and  
510 T481N, in line with to previous approaches (4) we used Neuro2A cells and adopted an  
511 electrophysiological protocol consisting of a voltage ramp from -80 mV to +80 mV. In physiologic  
512 isotonic conditions, the -80 mV step revealed leak inward currents in cells expressing mutants but not  
513 WT *TMEM63B* or control GCaMP6f, indicating that the variants lead to a gain in conductance even  
514 in the absence of the hypo-osmotic stimulus gating the channel.

515

516 Under a hypo-osmotic challenge, we measured similar values of inward current amplitude in both  
517 mutant and WT *TMEM63B* expressing Neuro2A cells, suggesting that the variants do not alter the  
518 maximal channel conductance. However, the overall increase between currents measured in hypo-  
519 osmotic and isotonic conditions was larger in WT than in mutant *TMEM63B* expressing cells.  
520 Similarly, the  $\text{Ca}^{2+}$  transients generated under hypo-osmotic stimulation were smaller across the  
521 mutant channels compared to the WT. One possible explanation for these observations is that V44M,  
522 R433H and T481N result in a selective reduction of the relative permeability for  $\text{Ca}^{2+}$  in favour of  
523  $\text{Na}^+$ .

524

525 Inward cationic leak currents in neural cells expressing *TMEM63B* mutants may lead to altered  
526 neuronal excitability and/or impaired  $\text{Ca}^{2+}$  homeostasis. In C57BL/6N-FVB/N *Tmem63b* knockout  
527 mice, progressive hearing loss due to necroptosis of the outer hair cells (OHCs) (4), which face severe  
528 shape- and volume-changing conditions, was suggested to reflect an abnormal response to osmotic  
529 and mechanical stimuli, ultimately leading to cell death (4).

530 Brain shrinking with white matter changes, the main imaging finding in our series, indicates defective  
531 myelination and, possibly, defective oligodendrocytes development. Clinical and imaging findings  
532 suggest that cell damage is already present at birth but further progresses postnatally. Already during  
533 prenatal life, several factors may determine osmotic challenges to the brain, including hydration  
534 changes, electrolytes imbalance and mechanical stress. In a brain where neural cells are exceedingly  
535 vulnerable to even trivial volume changes and electrolytic imbalances, recurrent seizures may, in a  
536 vicious circle, make *TMEM63B*-defective neurons particularly susceptible to osmotic imbalance.  
537 During seizure activity, the extracellular environment surrounding axons and oligodendrocytes  
538 undergoes changes in volume and osmolarity (32) and, given the very small volume of the  
539 extracellular space surrounding myelinated axons, oligodendrocytes might be subjected to continuous  
540 changes in local osmolarity. Unfortunately, our understanding of the homeostasis of the extracellular  
541 space is still in its infancy (33). In line with the above considerations, the epilepsy phenotype

542 observed in our cohort is considerably more severe compared to other neurological conditions  
543 featuring structural damage of similar magnitude (i.e., cerebral palsy due to vascular injury) (34).

544

545 In 12 patients, we also observed haematological abnormalities of variable severity, with signs of  
546 chronic haemolysis and myelodysplasia. In inherited haemolytic anaemias, abnormally shaped RBCs  
547 may reflect disorders of cation permeability in the membrane, resulting in cellular over- or de-  
548 hydration. Dehydrated hereditary stomatocytosis (DHSt), a rare congenital haemolytic anaemia, is  
549 caused by dominant GoF mutations of *PIEZO1*, encoding for a stretch-activated ion channel (35, 36).

550 In some patients with DHSt, hematologic abnormalities are subtle (35, 36), as also seen in most of  
551 our patients in whom they were revealed. In DHSt, *PIEZO1* mutations keep the channel in an open  
552 conformation with prolonged activity, resulting in  $\text{Ca}^{2+}$  influx and consequent  $\text{K}^{+}$  efflux through Ca-  
553 sensitive Gardos channels, decreasing intracellular osmolarity and causing dehydration of RBCs (36,  
554 37). Although the role of *TMEM63B* in RBCs remains to be elucidated, it is known to be expressed  
555 in the RBC membrane (<http://rbcc.hegelab.org/>) like *PIEZO1* and might act similarly.

556 Erythrocytes are highly deformable cells. The intense mechanical solicitations they face when  
557 circulating through the brain microvasculature require highly effective mechanosensory feedback  
558 mechanisms. Under normal healthy conditions, deformability of their membrane allows RBCs to flow  
559 through vessels of diameter less than the cell diameter (7-8  $\mu\text{m}$ ), ensuring robust tissue perfusion and  
560 oxygen delivery (38). This RBCs feature is particularly critical in the brain microvascular network,  
561 where the diameter of cortical capillaries is around 4-5  $\mu\text{m}$  (39). RBCs also play an active role in  
562 stabilizing neurovascular flow dynamics, both by their physical properties (40) and by targeting the  
563 vascular endothelium with vasoactive molecules (41). Chronic anaemic changes and the physical  
564 vulnerability of *TMEM63B*-defective RBCs might contribute to white matter abnormalities, which  
565 often predominate in watershed vascular areas in the patients reported here (Figure 1). Similar  
566 cerebrovascular complications are known to occur in patients with hereditary haemolytic anaemia  
567 (42).



568

569 In conclusion, *TMEM63B* developmental and epileptic encephalopathy represents a novel,  
570 clinicopathological entity deriving from the dysfunctional behaviour of a highly conserved stretch-  
571 activated ion channel. *TMEM63B* variants cause a gain in conductance with impaired  $\text{Ca}^{2+}$   
572 homeostasis and are associated with neurodegenerative changes that start during prenatal brain  
573 development and slowly progress during postnatal development and adulthood, affecting the cerebral  
574 white and grey matter, and cerebellum. The clinical counterpart of such widespread anatomic  
575 abnormalities includes severe early onset epilepsy, associated with moderate to profound intellectual  
576 disability and severe motor and cortical visual impairment. Although a clear genotype- phenotype  
577 correlation is not yet possible, the phenotype associated with the recurrent V44M variant is uniformly  
578 severe. Concomitant haematological changes make this a complex syndrome also featuring  
579 potentially life-threatening acute haemolytic episodes occurring without obvious triggers.

580

## 581 **Methods**

### 582 **Patients**

583 Our initial discovery cohort consisted of 600 consecutive patients referred to the Neuroscience  
584 Department of the Meyer Children's Hospital to investigate the genetic causes of DEEs. Within this  
585 cohort, we identified by whole exome sequencing (WES) (43) *de novo* heterozygous variants of  
586 *TMEM63B* in three patients (Pts 1-3) with a homogenous clinical and neuroimaging phenotype and  
587 promoted an international collaboration through GeneMatcher (44) identifying 13 additional patients  
588 carrying *de novo* *TMEM63B* variants (Pts 4-16). We reviewed medical records, EEGs, and brain MRI  
589 scans. We classified seizure types following the ILAE criteria (45), whenever applicable, and used  
590 more descriptive terms when seizure phenomenology could not fit classification terminology.  
591 Detailed methods for genetic investigations, protein structural analysis, functional characterization of  
592 *TMEM63B* variants, and *Drosophila* modelling are reported in the Supplementary material.



593

## 594 **Statistical analysis**

595 We used the GraphPad 8.0 software for statistical analyses. We assessed the normal distribution of  
596 experimental data using the D'Agostino-Pearson normality test. We analysed data with normal  
597 distribution with One-way ANOVA followed by Tukey's multiple comparison test, while for non-  
598 normally distributed data we used the unpaired Mann-Whitney U test or Kruskal-Wallis test followed  
599 by Dunn's multiple comparison test. We set significance level at  $p < 0.05$  and expressed data as mean  
600  $\pm$  standard error of the mean (SEM).

601 For statistical analysis of calcium imaging, we used the Origin 2019b package (OriginLab,  
602 Massachusetts, USA). Hypotheses were tested with Mann-Whitney non-parametric tests. We  
603 considered results to be significant for  $p < 0.05$ .

604

## 605 **Study approval**

606 We obtained written informed consent for the study from all participants or their legal guardians,  
607 according to local requirements. The study was approved by the Paediatric Ethics Committees of the  
608 Tuscany Region, Italy, in the context of the DESIRE FP7 EU project and its extension by the  
609 DECODE-EE project.

610

## 611 **Author contributions**

612 RG designed the research study, acquired and analysed clinical and genetic data, and drafted the  
613 manuscript; AV participated in designing research study, analysed genetic data, and drafted the  
614 manuscript; SB acquired and analysed clinical data, and participated in drafting the manuscript; CP  
615 analysed functional data, performed statistical analysis, and participated in drafting the manuscript;  
616 GMR participated in designing functional studies in transfected cells, analysed calcium imaging data,  
617 and performed statistical analysis; VC participated in designing functional studies, and in genetic and

618 protein structural data analysis; AM, GM, RP, and SG performed experimental analyses in transfected  
619 cells; KH and HO participated in protein structural data analysis; AD, CvS, EV, GB, JvdS, MK,  
620 MPM, MS, NM, RB, RR, SH, TB, and TR acquired clinical and genetic data; EA, EKB, JT, KW,  
621 MSc, RK, and SV acquired clinical data; AT, DM, DS, EHS, KM, KvG, MJVH, PC, and TC acquired  
622 genetic data; AS and TS produced and analysed *Drosophila* models.

623

### 624 **Data availability**

625 The data supporting the findings of this study are available within the article and/or its Supplementary  
626 material. Any additional raw data are available on request from the corresponding author.

627

### 628 **Acknowledgments**

629 We are grateful to all the Patients and family members for their participation in this study. This work  
630 was generated within the European Reference Networks EpiCARE and ITHACA.

631

### 632 **Funding**

633 This work was supported by grants to RG from the Tuscany Region Call for Health 2018 (grant  
634 DECODE-EE) and Fondazione Cassa di Risparmio di Firenze (Human Brain Optical Mapping  
635 Project). Support to EA in sequencing and analysis was provided by the Broad Institute of MIT and  
636 Harvard Center for Mendelian Genomics (Broad CMG) and by the National Human Genome  
637 Research Institute, the National Eye Institute, and the National Heart, Lung and Blood Institute grant  
638 UM1 HG008900 and in part by National Human Genome Research Institute grant R01 HG009141.  
639 AT was supported by Fondazione Telethon, Telethon Undiagnosed Diseases Program (grant  
640 GSP15001). NM from the Japan Agency for Medical Research and Development (AMED) under  
641 grant numbers JP22ek0109486, JP22ek0109549, and JP22ek0109493 and the Takeda Science

642 Foundation. TR was supported by the Australian NHMRC Centre for Research Excellence in  
643 Neurocognition (1117394).

644

645

## 646 **References**

- 647 1. Murthy SE et al. OSCA/TMEM63 are an evolutionarily conserved family of mechanically  
648 activated ion channels. *Elife* 2018;7. doi:10.7554/eLife.41844
- 649 2. Zhang M et al. Structure of the mechanosensitive OSCA channels. *Nat. Struct. Mol. Biol.*  
650 2018;25(9):850–858.
- 651 3. Yuan F et al. OSCA1 mediates osmotic-stress-evoked Ca<sup>2+</sup> increases vital for osmosensing in  
652 *Arabidopsis*. *Nature* 2014;514(7522):367–371.
- 653 4. Du H et al. The Cation Channel TMEM63B Is an Osmosensor Required for Hearing. *Cell Rep.*  
654 2020;31(5). doi:10.1016/j.celrep.2020.107596
- 655 5. Lang F et al. Functional significance of cell volume regulatory mechanisms. *Physiol. Rev.*  
656 1998;78(1). doi:10.1152/physrev.1998.78.1.247
- 657 6. Yan H et al. Heterozygous Variants in the Mechanosensitive Ion Channel TMEM63A Result in  
658 Transient Hypomyelination during Infancy. *Am. J. Hum. Genet.* 2019;105(5):996–1004.
- 659 7. Fukumura S et al. A novel de novo TMEM63A variant in a patient with severe hypomyelination  
660 and global developmental delay. *Brain Dev.* 2022;44(2):178–183.
- 661 8. Tonduti D et al. Spinal cord involvement and paroxysmal events in “Infantile Onset Transient  
662 Hypomyelination” due to TMEM63A mutation. *J. Hum. Genet.* 2021;66(10):1035–1037.
- 663 9. Tábara LC et al. TMEM63C mutations cause mitochondrial morphology defects and underlie  
664 hereditary spastic paraplegia. *Brain* 2022;145(9):3095–3107.
- 665 10. Wu D et al. Distant coupling between RNA editing and alternative splicing of the osmosensitive  
666 cation channel *tmem63b*. *J. Biol. Chem.* 2020;295(52). doi:10.1074/jbc.RA120.016049
- 667 11. Hou C et al. DUF221 proteins are a family of osmosensitive calcium-permeable cation channels  
668 conserved across eukaryotes. *Cell Res.* 2014;24(5). doi:10.1038/cr.2014.14
- 669 12. Maity K et al. Cryo-EM structure of OSCA1.2 from *Oryza sativa* elucidates the mechanical basis  
670 of potential membrane hyperosmolality gating. *Proc. Natl. Acad. Sci. U. S. A.* 2019;116(28).  
671 doi:10.1073/pnas.1900774116

- 672 13. Liu X, Wang J, Sun L. Structure of the hyperosmolality-gated calcium-permeable channel  
673 OSCA1.2. *Nat. Commun.* 2018;9(1). doi:10.1038/s41467-018-07564-5
- 674 14. Ittisoponpisan S et al. Can Predicted Protein 3D Structures Provide Reliable Insights into whether  
675 Missense Variants Are Disease Associated?. *J. Mol. Biol.* 2019;431(11).  
676 doi:10.1016/j.jmb.2019.04.009
- 677 15. Guo R et al. Structural cavities are critical to balancing stability and activity of a membrane-  
678 integral enzyme. *Proc. Natl. Acad. Sci. U. S. A.* 2020;117(36). doi:10.1073/pnas.1917770117
- 679 16. Marques MC, Albuquerque IS, Vaz SH, Bernardes GJL. Overexpression of Osmosensitive Ca<sup>2+</sup>-  
680 Permeable Channel TMEM63B Promotes Migration in HEK293T Cells. *Biochemistry* 2019;58(26).  
681 doi:10.1021/acs.biochem.9b00224
- 682 17. Zhao X, Yan X, Liu Y, Zhang P, Ni X. Co-expression of mouse TMEM63A, TMEM63B and  
683 TMEM63C confers hyperosmolarity activated ion currents in HEK293 cells. *Cell Biochem. Funct.*  
684 2016;34(4). doi:10.1002/cbf.3185
- 685 18. Iyer J et al. Quantitative Assessment of Eye Phenotypes for Functional Genetic Studies Using  
686 *Drosophila melanogaster*. *G3 Genes/Genomes/Genetics* 2016;6(5):1427–1437.
- 687 19. Kramer JM, Staveley BE. GAL4 causes developmental defects and apoptosis when expressed in  
688 the developing eye of *Drosophila melanogaster*. *Genet. Mol. Res.* 2003;2(1).
- 689 20. Brand AH, Perrimon N. Targeted gene expression as a means of altering cell fates and generating  
690 dominant phenotypes. *Development* 1993;118(2). doi:10.1242/dev.118.2.401
- 691 21. Andreu-Arasa VC, Chapman MN, Kuno H, Fujita A, Sakai O. Craniofacial manifestations of  
692 systemic disorders: CT and MR imaging findings and imaging approach. *Radiographics* 2018;38(3).  
693 doi:10.1148/rg.2018170145
- 694 22. Dickinson ME et al. High-throughput discovery of novel developmental phenotypes. *Nature*  
695 2016;537(7621):508–514.
- 696 23. Cacheiro P et al. Human and mouse essentiality screens as a resource for disease gene discovery.  
697 *Nat. Commun.* 2020;11(1). doi:10.1038/s41467-020-14284-2

- 698 24. Firth H V. et al. DECIPHER: Database of Chromosomal Imbalance and Phenotype in Humans  
699 Using Ensembl Resources. *Am. J. Hum. Genet.* 2009;84(4):524–533.
- 700 25. Turnbull C et al. The 100 000 Genomes Project: Bringing whole genome sequencing to the NHS.  
701 *BMJ* 2018;361. doi:10.1136/bmj.k1687
- 702 26. Lelieveld SH et al. Spatial Clustering of de Novo Missense Mutations Identifies Candidate  
703 Neurodevelopmental Disorder-Associated Genes. *Am. J. Hum. Genet.* 2017;101(3).  
704 doi:10.1016/j.ajhg.2017.08.004
- 705 27. Wilkie AOM. The molecular basis of genetic dominance. *J. Med. Genet.* 1994;31(2).  
706 doi:10.1136/jmg.31.2.89
- 707 28. Li Q, Montell C. Mechanism for food texture preference based on grittiness. *Curr. Biol.*  
708 2021;31(9):1850-1861.e6.
- 709 29. Li S, Li B, Gao L, Wang J, Yan Z. Humidity response in *Drosophila* olfactory sensory neurons  
710 requires the mechanosensitive channel TMEM63. *Nat. Commun.* 2022;13(1):3814.
- 711 30. Lal D et al. Gene family information facilitates variant interpretation and identification of disease-  
712 associated genes in neurodevelopmental disorders. *Genome Med.* 2020;12(1). doi:10.1186/s13073-  
713 020-00725-6
- 714 31. Guschanski K, Warnefors M, Kaessmann H. The evolution of duplicate gene expression in  
715 mammalian organs. *Genome Res.* 2017;27(9). doi:10.1101/gr.215566.116
- 716 32. Lux HD, Heinemann U, Dietzel I. Ionic changes and alterations in the size of the extracellular  
717 space during epileptic activity.. *Adv. Neurol.* 1986;44.
- 718 33. Sætra MJ, Einevoll GT, Haldnes G. An electrodiffusive neuron-extracellular-glia model for  
719 exploring the genesis of slow potentials in the brain. *PLoS Comput. Biol.* 2021;17(7).  
720 doi:10.1371/journal.pcbi.1008143
- 721 34. Cooper MS et al. Epilepsy syndromes in cerebral palsy: varied, evolving and mostly self-limited.  
722 *Brain* [published online ahead of print: July 24, 2022]; doi:10.1093/brain/awac274
- 723 35. Andolfo I et al. Multiple clinical forms of dehydrated hereditary stomatocytosis arise from

- 724 mutations in PIEZO1. *Blood* 2013;121(19):3925–3935.
- 725 36. Albuissou J et al. Dehydrated hereditary stomatocytosis linked to gain-of-function mutations in  
726 mechanically activated PIEZO1 ion channels. *Nat. Commun.* 2013;4. doi:10.1038/ncomms2899
- 727 37. Caulier A, Garçon L. PIEZO1, sensing the touch during erythropoiesis. *Curr. Opin. Hematol.*  
728 2022;29(3). doi:10.1097/MOH.0000000000000706
- 729 38. Ebrahimi S, Bagchi P. A computational study of red blood cell deformability effect on  
730 hemodynamic alteration in capillary vessel networks. *Sci. Rep.* 2022;12(1). doi:10.1038/s41598-022-  
731 08357-z
- 732 39. Schmid F, Barrett MJP, Jenny P, Weber B. Vascular density and distribution in neocortex.  
733 *Neuroimage* 2019;197. doi:10.1016/j.neuroimage.2017.06.046
- 734 40. Schmid F, Barrett MJP, Obrist D, Weber B, Jenny P. Red blood cells stabilize flow in brain  
735 microvascular networks. *PLoS Comput. Biol.* 2019;15(8). doi:10.1371/journal.pcbi.1007231
- 736 41. Richardson KJ, Kuck L, Simmonds J. Beyond oxygen transport: active role of erythrocytes in the  
737 regulation of blood flow. *Am. J. Physiol. - Hear. Circ. Physiol.* 2020;319(4).  
738 doi:10.1152/AJPHEART.00441.2020
- 739 42. Patel R, Sabat S, Kanekar S. Imaging Manifestations of Neurologic Complications in Anemia.  
740 *Hematol. Oncol. Clin. North Am.* 2016;30(4). doi:10.1016/j.hoc.2016.03.002
- 741 43. Vetro A et al. ATP1A2-and ATP1A3-associated early profound epileptic encephalopathy and  
742 polymicrogyria. *Brain* 2021;144(5). doi:10.1093/brain/awab052
- 743 44. Sobreira N, Schiettecatte F, Valle D, Hamosh A. GeneMatcher: a matching tool for connecting  
744 investigators with an interest in the same gene.. *Hum. Mutat.* 2015;36(10):928–30.
- 745 45. Scheffer IE et al. ILAE classification of the epilepsies: Position paper of the ILAE Commission  
746 for Classification and Terminology.. *Epilepsia* 2017;58(4):512–521.
- 747 46. Wiel L et al. MetaDome: Pathogenicity analysis of genetic variants through aggregation of  
748 homologous human protein domains. *Hum. Mutat.* 2019;40(8):humu.23798.

750 **Figure Legend**

751

752 **Figure 1 - Brain MRI in 15 patients with *TMEM63B* pathogenic variants.** Patients' numbers are  
753 shown in the upper left corner. For each patient, the corresponding *TMEM63B* variant is reported in  
754 the lower right corner. MRIs of the 10 patients who were imaged at least twice are shown. For Pts 1,  
755 4, 5, 7, 8, 14, and 16 two sets of comparative images are presented, from the initial (A) and follow-  
756 up (B) investigation. We show axial (left column), coronal (middle column), and sagittal (right  
757 column) images for all patients, except for Pt 16 where two axial (left and middle column) and one  
758 sagittal (right column) images are shown. For Pts 2, 3, 6, 10, 11-13, and 15, one set of axial (left  
759 column), coronal (middle column), and sagittal (right column) images is presented. Although Pts 2,  
760 12, 15 had serial MRIs, only one set of images is presented as either there were not significant changes  
761 or not all sets of images were available. Images were taken at 1.5 to 3T and include T<sub>1</sub>- or T<sub>2</sub>-weighted  
762 and FLAIR sequences. Structural abnormalities include a combination of white matter abnormalities,  
763 dysmorphic lateral ventricles, thinning of corpus callosum, cortical and cerebellar atrophy that are  
764 variably distributed. In Pt 1, at age 0-5 years, the main features include increased extracerebral spaces  
765 with enlarged cortical sulci, thin corpus callosum, with consequent colpocephaly, and high signal  
766 intensity of the hemispheric white matter, consistent with abnormal myelination. At a later follow-  
767 up, enlarged extracerebral spaces and thinning of the corpus callosum are less prominent but there is  
768 a definite high signal abnormality of the white matter, with dysmorphic lateral ventricles, and mild  
769 atrophy of the cerebellar cortex. In Pt 4, after a first MRI at age 0-5 years, only showing reduced  
770 volume of the frontal lobes, a follow-up scan revealed a progressive change in shape of the lateral  
771 ventricles and corpus callosum, both revealing white matter suffering, with mild atrophy of the  
772 cerebellar cortex. In Pts 5 and 8, changes that occurred from age 0-5 years over an interval of 1 to 9  
773 years are comparable to those observed in Pt 1. The abnormal ventricular shape causes ventricular  
774 asymmetry in these patients. Cerebellar atrophy is indicated by black arrows. In Pt 7 a second MRI



775 at age 0-5 years confirms the severe white matter abnormality, with dilated ventricles and thin corpus  
776 callosum already visible in the first images, and reveals mild progressive cerebellar atrophy (white  
777 arrow). In Pt 14, who was imaged twice 6-10 years apart, MRI images show as white matter changes  
778 and cerebellar atrophy continued to progress in adulthood, after age 26-30 (white arrow). In Pt 16,  
779 only minor changes occurred between age 0-5 and 11-15 years, with no clear worsening. At 0-5 years,  
780 there were areas of abnormal myelination, especially on the right hemisphere and a thin corpus  
781 callosum with colpocephaly. At age 11-15, the corpus callosum remained thin but because of  
782 maturation processes was thicker than before and ventricular dilatation less prominent, with mild  
783 peritrigonal high signal intensity abnormality. In Pt 2, brain MRI, taken at 6-10 years, shows bilateral  
784 patchy areas of white matter abnormalities highlighted by a circle in the left frontal and right temporal  
785 regions. This finding, in association with focal seizures had initially raised the suspicion of areas of  
786 focal cortical dysplasia. Additional findings include ventricular asymmetry, thin corpus callosum and  
787 cerebellar atrophy. Cerebellar atrophy had progressed when compared with previous imaging taken  
788 at age 6-10 years (images not shown). In Pt 3, who was imaged at 0-5 years, there are multifocal high  
789 signal white matter changes with dysmorphic and asymmetric lateral ventricles, thin corpus callosum,  
790 and enlarged cortical sulci. Pts 6 and 10, both imaged at age 0-5 years, exhibited increased  
791 extracerebral spaces with enlarged sulci, thin corpus callosum, and reduced signal intensity of the  
792 white matter, consistent with abnormal myelination. The abnormal myelination is more obvious  
793 posteriorly in Pt 10 (white circles). In Pt 11, at age 6-10 years, there were only multifocal areas of  
794 white matter abnormalities without atrophic changes. Pts 12, 13, and 15 imaged between 0-5 and 6-  
795 10 years, show similar findings, slightly varying in severity and including a thin corpus callosum,  
796 areas of abnormal signal intensity of the white matter with posterior predominance (present in all),  
797 dilated asymmetric ventricles (Pts 12 and 13), and mild cerebellar atrophy (Pts 13). In Pts 4, 8, 12,  
798 and 14 thickening of the trabecular (spongy) bone of the skull (indicated by the asterisks) is suggestive  
799 of a blood disorder.

800

801 **Figure 2 - Genetic results.** (A) The lollipop diagram shows the distribution of the TMEM63B  
802 variants observed in our cohort on the linear protein map and relative to the *TMEM63B* exons (top,  
803 based on NM\_018426.3 sequence). The variants are represented as green (missense substitutions) or  
804 brown (in-frame deletion) dots and all map in the transmembrane helices TM1, TM4-7, and TM9-10  
805 (green boxes). The V44M is recurrent in seven patients, as illustrated by the number of green dots.  
806 At the bottom of the diagram, the dark blue dots represent the residues affected by missense variants  
807 in *TMEM63A* (five variants in six unrelated patients: G168E, I462N, G553V, Y559H, G567S) (6–8).  
808 (B) Tolerance landscape plot of the TMEM63B protein provided by the MetaDome web server  
809 (<https://stuart.radboudumc.nl/metadome/>). The tool identifies regions of low tolerance to missense  
810 variations based on the local non-synonymous over synonymous variants ratio from GnomAD (46).  
811 All variants in our cohort are contained in intolerant/highly intolerant regions (in red) of the  
812 landscape. (C) Multiple sequence alignment shows the protein sequence of the human TMEM63B  
813 protein (NP\_060896.1) and of its orthologues in five different vertebrate species (*Pan troglodytes*,  
814 *Sus scrofa*, *Mus musculus*, *Gallus gallus*, *Danio rerio*), with the mutated residues in bold. The details  
815 of the TMEM63B variants in the cohort are displayed above the alignments. The asterisk below the  
816 sequence indicates positions which have a single, fully conserved residue between all the input  
817 sequences, the colon indicates conservation between groups of strongly similar properties, and the  
818 period indicates conservation between groups of weakly similar properties.

819

820 **Figure 3 - Structural consideration of TMEM63B pathogenic variants.** View of the predicted  
821 tridimensional protein structure of TMEM63B from the membrane plane (A) and the extracellular  
822 side (B). All the variants in our cohort map into a transmembrane (TM) helix: V44M in TM1 (dark  
823 green helix), R433H, D459E, V463I, I475del, and T481N in TM4 and TM5 (blue helices), G580S in  
824 TM7 (orange helix), R660T in TM8 (pink helix), and F697L in TM9 (light green helix). Dotted line  
825 in (A) indicate the plasma membrane, OUT the extracellular side and IN the intracellular  
826 (cytoplasmic) side. Details of selected variants are provided in the inlets. (C) Predicted structural

827 change induced by the D459E substitution. The OD2 atom of Asp459 is predicted to form a buried  
828 salt bridge with NZ atom of Lys460 (K460). The substitution of an aspartic acid with a glutamic acid  
829 at position 459 increases the distance between the NZ atom of Lys460 and the closer oxygen atom  
830 (OE2) available to make a salt bridge, breaking this bond. (D) Predicted structural change induced  
831 by the G580S substitution. The substitution of a glycine (green) with a bulkier amino acid (serine,  
832 orange) changes the RSA of the amino acid at position 580 (5.9% to 3.8%). In addition, OG atom of  
833 Ser580 might form a salt bridge with NE1 atom of Trp485 (W485) and help in stabilizing the structure  
834 of the pore. (E) Predicted structural change induced by the G580C substitution. The substitution of a  
835 Glycine (green) with a bulkier amino acid (Cysteine, orange) changes the RSA of the amino acid at  
836 position 580 (5.9% to 3.7%). Although the substitution introduces an amino acid with a free SH group  
837 which can make disulphide bonds with other amino acids with free SH groups (depicted as yellow  
838 spheres), the distance between C580 and the closer amino acid with a free SH group (C486, 10.519Å)  
839 is too big to allow the making of such type of bond. (F) Predicted structural change induced by the  
840 R660T substitution. The substitution of a buried charged residue (Arginine) with an uncharged  
841 residue (Threonine) at position 660 disrupts a salt bridge formed by NH2 atom of Arg660 and Asp137  
842 (D137).

843

844 **Figure 4 - Immunocytochemistry to assess TMEM63B localisation at the plasma membrane.**

845 Confocal microscopy photographs of Neuro2A cells transfected with GCaMP6f empty vector,  
846 TMEM63B WT or mutant plasmids and analysed 48 hours post transfection. Transfected cells  
847 express the GCaMP6f protein which fluoresces in the green channel. Cells were stained with primary  
848 anti HA tag antibody, secondary Alexa Fluor 555 antibody and DAPI. Scale bar = 10 µm.

849

850 **Figure 5 - Electrophysiological recordings on transfected Neuro2A cells.** (A) Left panel:

851 representative raw traces of TMEM63B-mediated currents registered under isotonic condition in  
852 Neuro2A cells transfected with GCaMP6f, TMEM63B WT or mutant plasmids. Cells were held at 0

853 mV and recorded with a ramp protocol from  $-80$  mV to  $+80$  mV, 100 ms duration, 0.1 Hz. Right  
854 panel: current-voltage (I-V) relationship showing variant-induced change in reversal potential. (B-C)  
855 Quantification of whole-cell current density at  $-80$ mV (B) and  $+80$ mV (C) (GCaMP6f = 16 cells, WT  
856 TMEM63B = 18 cells, TMEM63B V44M, R433H and T481N = 17 cells; \*\*\*\* $p < 0.0001$ , \*\* $p < 0.01$ ,  
857 \* $p < 0.05$ , ns = not significant, Kruskal–Wallis and Dunn's multiple comparisons tests). (D)  
858 Quantification of reversal potential (GCaMP6f= 15 cells, WT TMEM63B = 17 cells, TMEM63B  
859 V44M = 16 cells, TMEM63B R433H = 17 cells, TMEM63B T481N = 16 cells; \*\*\*\* $p < 0.0001$ , One-  
860 way ANOVA and Tukey's multiple comparison test).

861

862 **Figure 6 - Mutations of TMEM63B impair the  $Ca^{2+}$  response to hypotonic stress. (A)**  
863 Representative time-lapse sequence of Neuro2A cells co-transfected with WT and V44M TMEM63B  
864 after exposure to hypo-osmotic solution (170 mOsm/L). For each genotype we show two cells  
865 characterized by transient or steady responses. The green dots on the traces indicates the timing of  
866 the images. Calibration bar is 10  $\mu$ m in all images. (B) Fraction of Neuro2A cells transfected with  
867 WT, V44M, R443H, or T481N TMEM63B presenting a  $Ca^{2+}$  response within 10 min from exposure  
868 to hypo-osmotic solutions. The number of analysed cells is on top of each column, with the number  
869 of replicates in parenthesis. (C) Representative traces showing the change of fluorescence for several  
870 cells transfected with WT, V44M, R443H, or T481N TMEM63B. (D) Cumulative results indicating  
871 the peak amplitude of the  $Ca^{2+}$  response to hypo-osmotic stimulus (255 mOsm/L). Numbers indicate  
872 the responding cells in each group. Total number of analysed cells and replicates as indicated in panel  
873 B. (E) Integral of the  $Ca^{2+}$  change for the indicated experimental groups. In this analysis we included  
874 only the cells that returned to baseline within 150 s from the transient onset. All mutant showed a  
875 drastically reduced response. Abbreviations and symbols: \*\*\*,  $p < 0.001$ ; \*\*,  $p < 0.01$ ; \*,  $p < 0.05$  (Chi-  
876 Square test); GCaM, control cells transfected with GCaMP6f empty vector.

877

**Table 1 - Clinical features of the 16 patients with *TMEM63B* variants**

<b>Patient number/gender</b>	<b>TMEM63B variant (cDNA and protein)/abbreviated</b>	<b>Age at last follow-up/death</b>	<b>Type of seizure at onset</b>	<b>Seizure types/severity during follow-up</b>	<b>Treatment ever tried</b>	<b>EEG</b>	<b>Brain magnetic resonance imaging</b>	<b>Clinical neurological phenotype</b>	<b>Haematological findings</b>
<b>1/M</b>	c.130G>A p.(Val44Met)/V44M	6-10y	Infantile spasms	Spasms, myoclonic, focal with impaired awareness/daily	CZP, ESM, PB, VGB	Slow background, bilateral independent discharges; epileptic spasms and myoclonic szs	0-5y: thin CC, colpocephaly, abnormal myelination, dysmorphic lateral ventricles, enlarged extracerebral spaces, progressive mild cerebellar atrophy, and watershed areas WM abnormality	Threatened preterm labour at 35w, global profound DD, generalised hypotonia, plagiocephaly, nystagmus, dysphagia (PEG 0-5y), dyskinesias	Mild anaemia
<b>2/M</b>	c.1298G>A p.(Arg433His)/R433H	6-10y	Focal	Bilateral independent focal motor with impaired awareness, focal to bilateral tonic-clonic/weekly	CBZ, CLB, CZP, LEV, LCM, MDZ, PB, PHT, STP, TPM	Slow background, multifocal discharges; focal szs recorded	6-10y: thin CC, multifocal WM abnormalities, ventricular asymmetry, progressive cerebellar atrophy	Global profound DD, ataxic gait, lower limb hypertonia, nystagmus	Mild abnormalities of RBCt, MCV, MCH
<b>3/M</b>	c.1442C>A p.(Thr481Asn)/T481N	11-15y	Focal motor with asymmetric posturing	Focal with impaired awareness and asymmetric posturing, focal to bilateral tonic-clonic/weekly	CBZ, CLB, PB, PER, STP, VGB, VNS	Slow background, focal epileptiform discharges	0-5y: thin CC, posterior predominant multifocal WM abnormalities, dysmorphic asymmetric lateral ventricles, enlarged cortical sulci	Global profound DD, spastic asymmetric quadriparesis, severe cortical visual impairment	None
<b>4/M #</b>	c.130G>A p.(Val44Met)/V44M	11-15y/deceased at 11-15y (pneumonia)	Focal	Focal with impaired awareness; spasms and focal to bilateral tonic-clonic/daily. Single episode of SE	CBZ, CLB, KD, LTG, LEV, PRED, RFM, VGB, VPA, VNS	Slow background, bilateral independent or multifocal discharges; epileptic spasms recorded	0-5y, 6-10y: thin CC, multifocal WM abnormalities, dysmorphic enlarged lateral ventricles, mild cortical and cerebellar atrophy, progressive trabecular bone thickening	Global profound DD, wheelchair-bound, cortical visual impairment, by 10y knee fixed flexion contractures, dysphagia (PEG 0-5y)	Severe macrocytic anaemia transfusion-dependent
















<b>5/M</b>	c.130G>A p.(Val44 Met)/V44 M	6-10y	Apnoeic	Epileptic spasms; focal hyperkinetic motor with impaired awareness/sz-free	CBZ(+), CLB, LEV, PB (+), TPM (+)	Slow background, bilateral independent or multifocal discharges; focal szs recorded	0-5y: thin CC, abnormal myelination, dysmorphic asymmetric lateral ventricles, enlarged extracerebral spaces, progressive posteriorly predominant WM abnormality and cerebellar atrophy	Global profound DD, severe cortical visual impairment, nystagmus, spastic quadriparesis, dysphagia (PEG 0-5y)	Jaundice at birth
<b>6/F #</b>	c.130G>A p.(Val44 Met)/V44 M	0-5y/ deceased at 0-5y (pneumonia in progressive respiratory failure)	Apnoeic	Focal onset with impaired awareness, focal to bilateral tonic- clonic, epileptic spasms/daily	Alimemazine, CBZ, CLB, PB (+/-), paraldehyde, PRED, TPM, VGB, VPA, VNS(+), biotin, pyridoxine	Slow background, multifocal or generalised discharges with burst suppression; focal szs recorded	0-5y: thin CC, enlarged extracerebral spaces, diffusely abnormal myelination	Global profound DD, quadriparesis with generalised hypotonia, cortical visual impairment, nystagmus, dysphagia (PEG 0-5y)	Macrocytic anaemia, transfusion- dependent
<b>7/M #</b>	c.130G>A p.(Val44 Met)/V44 M	0-5y	Apnoeic	Stiffening episodes; epileptic spasms/sz-free	LEV, steroids, VGB	Normal background, then hypsarrhythmia, slow background, focal discharges	0-5y: thin CC, widespread WM abnormalities, enlarged dysmorphic lateral ventricles, mild progressive cerebellar atrophy	Global profound DD, asymmetric quadriparesis, generalised hypotonia, cortical visual impairment, nystagmus, dysphagia (no PEG yet)	Scleralicterus
<b>8/F</b>	c.130G>A p.(Val44 Met)/V44 M	16-20y	Infantile spasms	Generalised tonic, focal motor with impaired awareness/daily	ACTH, CBZ, CLB, CZP, ESM, GBP, ivIg, LCM, LEV, PB, PER, PIR, PLP, PRM, STP, TPM, VPA, ZNS	Hypsarrhythmia, then slow background, multifocal epileptiform discharges	0-5y, 6-10y: thin CC, abnormal myelination, dysmorphic asymmetric lateral ventricles, enlarged extracerebral spaces, progressive widespread WM abnormality, ventricular dilatation, cerebellar atrophy, and trabecular bone thickening	Global profound DD, quadriparesis, dysphagia (PEG 11- 15y)	Severe anaemia requiring occasional transfusions
<b>9/M</b>	c.130G>A p.(Val44 Met)/V44 M	11-15y	Febrile seizures	Epileptic spasms, in small clusters/ weekly	CZP, VPA	Slow background, no epileptiform discharges in 4 EEG recordings	0-5y: thin CC with absent splenium and delayed myelination; 6-10y increased signal of WM in watershed areas, generalized decrease of white matter volume	Global profound DD, wheelchair-bound, quadriparesis, pseudobulbar signs, jerky involuntary movements, stereotypical movements and behaviour, dysphagia	Mild anaemia



								(PEG 0-5y). Cortical visual impairment, nystagmus	
<b>10/F</b>	c.1377C>G p.(Asp459Glu)/D459E	0-5y	Focal	Bilateral independent focal, epileptic spasms/daily	CBD, KD, LEV, VGB, VNS, ZNS	Slow background, hypsarrhythmia, multifocal discharges; focal szs and epileptic spasms recorded	0-5y: thin CC, enlarged extracerebral spaces, abnormal myelination more pronounced posteriorly, Rathke cleft cyst	Global profound DD, quadriplegia, generalised hypotonia, cortical blindness with roving eye movements, dysphagia	Mild macrocytic anaemia
<b>11/M</b>	c.1387G>A p.(Val463Ile)/V463I	6-10y	Focal	Occasional focal with impaired awareness/during fever	VPA	Normal background, bilateral independent discharges	6-10y: multifocal, posteriorly predominant WM abnormality	Global severe DD, motor impairment, generalised hypotonia	None
<b>12/F</b>	c.1424_1426del p.(Ile475del)/I475del	16-20y	Infantile spasms	Tonic/daily; GTCs /monthly	ACTH, CBD, CLB, CZP, LEV, LTG, OXC, TPM (-), VGB(-), VPA	Hypsarrhythmia, then slow background, bilateral independent or multifocal discharges; epileptic spasms and tonic szs recorded	0-5y, 6-10y: thin CC, multifocal WM abnormalities, asymmetric dysmorphic lateral ventricles, progressive trabecular bone thickening	Global profound DD, generalised hypotonia, microcephaly, visual impairment, nystagmus, squint, spastic quadriplegia, dysphagia (PEG 11-15y), scoliosis	Severe haemolytic anaemia, transfusion-dependent
<b>13/M</b>	c.1738G>A p.(Gly580Ser)/G580S	0-5y	Focal	GTCs/occasional during fever	VPA	Slow background, focal discharges	0-5y: thin CC, widespread WM abnormality, especially periventricular, asymmetric dysmorphic lateral ventricles, mild cerebellar atrophy	Global profound DD, spastic quadriplegia, axial hypotonia, upper limb dystonia, visual impairment, dysphagia (PEG 0-5y)	None
<b>14/F</b>	c.1738G>T p.(Gly580Cys)/G580C	26-30y	Focal	Focal with impaired awareness, GTCs/yearly	CBZ, CZP, PHT(+), VPA, ZNS	Slow background, focal discharges; focal szs recorded	11-15y, 21-25y, and 26-30y: thin CC, widespread WM abnormality, especially periventricular/posterior, progressive cerebellar atrophy, and trabecular bone thickening	Global moderate DD, cerebellar ataxia, tremor, dysarthria, limited mobility, bipolar disorder	Mild hyperbilirubinaemia
<b>15/F</b>	c.1979G>C p.(Arg660Thr)/R660T	21-25y	Focal	Focal with posturing and impaired awareness, recurrent SE/yearly	CBZ(-), LMT(-), OXC, PB(-), TPM, VNS (+)	Background mildly abnormal, diffuse beta activity, multifocal discharges; focal szs recorded.	0-5y, 6-10y: thin CC, multifocal WM abnormality	Global moderate DD, spastic quadriplegia, ASD	Macrocytic anaemia

<b>16/M</b>	c.2089T> C p.(Phe697 Leu)/F697 L	11-15y	Focal	Focal with eye deviation-jerking, GTCs, recurrent SE/sz-free at last FU	CLB, LTG(-), LEV(-), OXC, PHT, VPA	Normal background; focal discharges	0-5y, 11-15y: thin CC, abnormal myelination, colpocephaly, dysmorphic lateral ventricles, increase WM signal with posterior/periventricular predominance	Global, severe DD, toe walking, ASD	None
-------------	--	--------	-------	---	--	--	---	--	------

Abbreviations and symbols: ASD, autism spectrum disorder; CBD, cannabidiol; CBZ, carbamazepine; CC, corpus callosum; CLB, clobazam; CZP, clonazepam; DD, developmental delay; ESM, ethosuximide; F, female; GBP, gabapentin; GTCS, generalized tonic-clonic seizures; ivIg, intravenous Immunoglobulin; KD, ketogenic diet; LCM, lacosamide; LEV, levetiracetam; LTG, lamotrigine ; M, male; MCH, mean corpuscular haemoglobin; MCV, mean corpuscular volume; MDZ, midazolam; NA, not available; OXC, oxcarbazepine; PB, phenobarbital; PEG, percutaneous endoscopic gastrostomy; PER, perampanel; PHT, phenytoin; PIR, piracetam; PLP, pyridoxal 5'-phosphate; PRED, prednisolone; PRM, primidone; RBC, red blood cells; RFM, rufinamide; SE, status epilepticus; STP, stiripentol; sz, seizure; TGP, targeted gene panel; TPM, topiramate; VGB, vigabatrin; VNS, vagus nerve stimulation; VPA, valproic acid; WM, white matter; y, years; ZNS, zonisamide; #, Pts 4, 6 and 7 are mentioned in Cacheiro et al, 2020 (23)(Supplementary Table S8: DDD patient1, 100KGP patient 2, and 100KGP patient 1); treatment ever tried: +, efficacy; +/-, transient efficacy; -, worsening or not tolerated.













**C**

	V44M	R433H	D459E	V463I	I475del	T481N
Human ( <i>H. sapiens</i> )	LPFGGVPT <b>VL</b> LALDFMCF	IRGFIW <b>WL</b> RCLVINVV <b>L</b>	IIIT <b>MD</b> DKFN <b>V</b> TKPVEY	NNPI <b>IT</b> QFFP <b>T</b> LL <b>L</b> WCF	487	
Chimp ( <i>P. troglodytes</i> )	LPFGGVPT <b>VL</b> LALDFMCF	IRGFIW <b>WL</b> RCLVINVV <b>L</b>	IIIT <b>MD</b> DKFN <b>V</b> TKPVEY	NNPI <b>IT</b> QFFP <b>T</b> LL <b>L</b> WCF	487	
Pig ( <i>S. scrofa</i> )	LPFGGVPT <b>VL</b> LALDFMCF	IRGFIW <b>WL</b> RCLVINVV <b>L</b>	IIIT <b>MD</b> DKFN <b>V</b> TKPVEY	NNPI <b>IT</b> QFFP <b>T</b> LL <b>L</b> WCF	487	
Mouse ( <i>M. musculus</i> )	LPFGGVPT <b>VL</b> LALDFMCF	IRGFIW <b>WL</b> RCLVINVV <b>L</b>	IIIT <b>MD</b> DKFN <b>V</b> TKPVEY	NNPI <b>IT</b> QFFP <b>T</b> LL <b>L</b> WCF	487	
Chicken ( <i>G. gallus</i> )	LPFGGVPT <b>VL</b> LALDFMCF	IRGFIW <b>WL</b> RCLVINVV <b>L</b>	IIIT <b>MD</b> DKFN <b>V</b> TKPVEY	NNPI <b>IT</b> QFFP <b>T</b> LL <b>L</b> WCF	493	
Zebrafish ( <i>D. rerio</i> )	LPFGGVPT <b>VL</b> LALDFMCF	ISGLN <b>W</b> W <b>V</b> R <b>C</b> FVIN <b>C</b> L	IIIT <b>MD</b> DKFN <b>V</b> TKPVEY	NNPI <b>V</b> T <b>Q</b> FFP <b>T</b> LL <b>L</b> WCF	490	
	*****	* * : * * : * * : * * *	* * * : * * * * * * * * * *	* * * * : * * * * * * * * * *		

	G580S G580C	R660T	F697L	
Human ( <i>H. sapiens</i> )	VNYVIASAFI <b>GN</b> AMDLLRIPG	MYMLL <b>KL</b> HLVD <b>R</b> YNLYYAYLPA	APILCLFW <b>LL</b> FFSTMR <b>T</b> GFLA	707
Chimp ( <i>P. troglodytes</i> )	VNYVIASAFI <b>GN</b> AMDLLRIPG	MYMLL <b>KL</b> HLVD <b>R</b> YNLYYAYLPA	APILCLFW <b>LL</b> FFSTMR <b>T</b> GFLA	707
Pig ( <i>S. scrofa</i> )	VNYVIASAFI <b>GN</b> AMDLLRIPG	MYMLL <b>KL</b> HLVD <b>R</b> YNLYYAYLPA	APILCLFW <b>LL</b> FFSTMR <b>T</b> GFLA	707
Mouse ( <i>M. musculus</i> )	VNYVIASAFI <b>GN</b> AMDLLRIPG	MYMLL <b>KL</b> HLVD <b>R</b> YNLYYAYLPA	APILCLFW <b>LL</b> FFSTMR <b>T</b> GFLA	707
Chicken ( <i>G. gallus</i> )	VNYVIASAFI <b>GN</b> AMDLLRIPG	MYMLL <b>KL</b> HLVD <b>R</b> YNLYYAYLPA	APILCLFW <b>LL</b> FFSTMR <b>T</b> GFLA	713
Zebrafish ( <i>D. rerio</i> )	VNYVIASAFI <b>GN</b> AMDLLRIPY	MYMLL <b>KL</b> HLVD <b>R</b> YNMYAYLPS	APILC <b>I</b> FW <b>LL</b> FFSTVR <b>Q</b> GFGA	710
	*****	***** : * * * * * : * * * * * : * * * * *	* * * * : * * * * * * * * * * * * * * *	

























DAPI





GCaMP6f

HA tag


Merged

GCaMP6f


TMEM63B  
WTTMEM63B  
V44MTMEM63B  
R433HTMEM63B  
T481N




A




C



B



D



E

